Abstract
Increasing knowledge of the structure and function of the Epidermal Growth Factor Receptor (EGFR) subfamily of tyrosine kinases, and of their role in the initiation and progression of various cancers has led to the search for inhibitors of signaling molecules that may prove to be important in cancer therapy. The complex nature of EGFR biology allows for potential opportunities for EGFR inhibitors in a number of areas of cancer therapy, including proliferative, angiogenic, invasive, and metastatic aspects. Different approaches have been used to target either the extracellular ligand-binding domain of the EGFR or the intracellular tyrosine kinase region that results in interference with its signaling pathways that modulate cancer-promoting responses. Examples of these include a number of monoclonal antibodies, immunotoxins and ligand-binding cytotoxic agents that target the extracellular ligand binding region of EGFR, and small molecule inhibitors that target the intracellular kinase domain and act by interfering with ATP binding to the receptor. During the past 3 years, significant progress has been made towards the identification of new structural classes of small molecule inhibitors that show high potency and specificity towards EGFR. The search for new small molecules that inhibit kinases has included traditional approaches like the testing of natural products, random screening of chemical libraries, the use of classical structure-activity-relationship studies, and the incorporation of structurebased drug design and combinatorial chemistry techniques. There has been a significant improvement in the development of selective EGFR inhibitors with the use of a structure-based design approach employing a homology model of the EGFR kinase domain. Molecular modeling procedures have been used to generate novel molecules that are complementary in shape and electrostatics to the EGFR kinase domain topography. This review focuses on some examples of the successful use of this method.
Current Cancer Drug Targets
Title: Rational Design of Potent and Selective EGFR Tyrosine Kinase Inhibitors as Anticancer Agents
Volume: 1 Issue: 2
Author(s): Sutapa Ghosh, Xing-Ping Liu, Yaguo Zheng and Fatih M. Uckun
Affiliation:
Abstract: Increasing knowledge of the structure and function of the Epidermal Growth Factor Receptor (EGFR) subfamily of tyrosine kinases, and of their role in the initiation and progression of various cancers has led to the search for inhibitors of signaling molecules that may prove to be important in cancer therapy. The complex nature of EGFR biology allows for potential opportunities for EGFR inhibitors in a number of areas of cancer therapy, including proliferative, angiogenic, invasive, and metastatic aspects. Different approaches have been used to target either the extracellular ligand-binding domain of the EGFR or the intracellular tyrosine kinase region that results in interference with its signaling pathways that modulate cancer-promoting responses. Examples of these include a number of monoclonal antibodies, immunotoxins and ligand-binding cytotoxic agents that target the extracellular ligand binding region of EGFR, and small molecule inhibitors that target the intracellular kinase domain and act by interfering with ATP binding to the receptor. During the past 3 years, significant progress has been made towards the identification of new structural classes of small molecule inhibitors that show high potency and specificity towards EGFR. The search for new small molecules that inhibit kinases has included traditional approaches like the testing of natural products, random screening of chemical libraries, the use of classical structure-activity-relationship studies, and the incorporation of structurebased drug design and combinatorial chemistry techniques. There has been a significant improvement in the development of selective EGFR inhibitors with the use of a structure-based design approach employing a homology model of the EGFR kinase domain. Molecular modeling procedures have been used to generate novel molecules that are complementary in shape and electrostatics to the EGFR kinase domain topography. This review focuses on some examples of the successful use of this method.
Export Options
About this article
Cite this article as:
Ghosh Sutapa, Liu Xing-Ping, Zheng Yaguo and Uckun M. Fatih, Rational Design of Potent and Selective EGFR Tyrosine Kinase Inhibitors as Anticancer Agents, Current Cancer Drug Targets 2001; 1 (2) . https://dx.doi.org/10.2174/1568009013334188
DOI https://dx.doi.org/10.2174/1568009013334188 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of PPAR in Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Polyploidy: The Link Between Senescence and Cancer
Current Pharmaceutical Design Design, Synthesis and In-Vitro Evaluation of Polymer-linked Prodrug of Methotrexate for the Targeted Delivery to the Colon
Letters in Drug Design & Discovery β-sitosterol: Bioactive Compounds in Foods, their Role in Health Promotion and Disease Prevention “A Concise Report of its Phytopharmaceutical Importance”
Current Traditional Medicine Converting Human Proteins into Precision Polymer Therapeutics
Current Pharmaceutical Design Subject Index to Volume 5
Current Drug Targets PPAR-Gamma in Ulcerative Colitis: A Novel Target for Intervention
Current Drug Targets Chitosan Nanoparticles for Melanoma Cancer Treatment by Photodynamic Therapy and Electrochemotherapy Using Aminolevulinic Acid Derivatives
Current Medicinal Chemistry Anti-HER2 Therapy in Elderly Breast Cancer Patients
Reviews on Recent Clinical Trials TREM2 and the Progression of Alzheimer’s Disease
Current Neurovascular Research Genetic Polymorphisms of Drug Metabolizing Enzymes and Transporters: The Long Way from Bench to Bedside
Current Topics in Medicinal Chemistry Cathepsin L Induces Proangiogenic Changes in Human Omental Microvascular Endothelial Cells via Activation of the ERK1/2 Pathway
Current Cancer Drug Targets The Battle of the Sexes for Stroke Therapy: Female- Versus Male-Derived Stem Cells
CNS & Neurological Disorders - Drug Targets Rapid Characterization of a Novel Taspine Derivative-HMQ1611 Binding to EGFR by a Cell Membrane Chromatography Method
Combinatorial Chemistry & High Throughput Screening A Key Role for Connexin Hemichannels in Spreading Ischemic Brain Injury
Current Drug Targets Nanoparticulate Drug Delivery in Pregnancy: Placental Passage and Fetal Exposure
Current Pharmaceutical Biotechnology Nanoparticle-based Drug Delivery Systems for Targeted Epigenetics Cancer Therapy
Current Drug Targets Aberrant Splicing, Hyaluronan Synthases and Intracellular Hyaluronan as Drivers of Oncogenesis and Potential Drug Targets
Current Cancer Drug Targets BioMEMS in Diagnostics: A Review and Recent Developments
Recent Patents on Engineering EDITORIAL (Thematic Issue: Special Thematic Issuue: Development of Biomarkers in Tumors of Digestive System Part I)
Anti-Cancer Agents in Medicinal Chemistry